Protalix BioTherapeutics Files 8-K on Shareholder Vote Matters

TL;DR

PLX filed an 8-K for shareholder vote matters and exhibits. Keep an eye on the vote outcome.

AI Summary

On June 27, 2024, Protalix BioTherapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal business address is in Hackensack, NJ.

Why It Matters

This filing indicates important corporate actions are being put to a shareholder vote, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: low — This is a routine filing related to corporate governance and financial reporting, not indicating immediate operational or financial distress.

Key Players & Entities

• Protalix BioTherapeutics, Inc. (company) — Registrant
• June 27, 2024 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of incorporation
• Hackensack, NJ (location) — Business Address

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common stock, $0.001 par value PLX NYSE American Indic

Filing Documents

• plx-20240627x8k.htm (8-K) — 61KB
• plx-20240627xex10d1.htm (EX-10.1) — 607KB
• 0001558370-24-009567.txt ( ) — 849KB
• plx-20240627.xsd (EX-101.SCH) — 3KB
• plx-20240627_lab.xml (EX-101.LAB) — 16KB
• plx-20240627_pre.xml (EX-101.PRE) — 11KB
• plx-20240627x8k_htm.xml (XML) — 5KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders Protalix Biotherapeutics, Inc. (the "Company") convened its 2023 Annual Meeting of Stockholders (the "Meeting") at 11:30 A.M. EDT on June 27, 2024 at the offices of LifeSci Advisors, 250 W. 55th Street, Suite 3401, New York, NY 10019. At the Meeting, the Company's stockholders: (1) elected the seven persons nominated by the Company's Board of Directors to serve as directors of the Company; (2) approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers; (3) adopted amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), available under such plan from 12,475,171 shares to 17,475,171 shares and adopted certain other terms of said plan; and (4) ratified the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Set forth below, with respect to each proposal adopted at the Meeting, are the number of votes cast for or against or withheld, as applicable, the number of abstentions and the number of broker non-votes. (1) Election of Directors For Withheld Broker Non-Votes Eliot Richard Forster, Ph.D. 22,800,329 4,532,876 14,294,931 Dror Bashan 22,359,235 4,973,970 14,294,931 Amos Bar Shalev 14,916,342 12,416,863 14,294,931 Shmuel "Muli" Ben Zvi, Ph.D. 22,781,806 4,551,399 14,294,931 Pol F. Boudes, M.D. 22,866,402 4,466,803 14,294,931 Gwen A. Melincoff 22,884,691 4,448,514 14,294,931 Aharon Schwartz, Ph.D. 20,105,843 7,227,362 14,294,931 (2) Approval, on a non-binding, advisory basis, the compensation of the Company's named executive officers For Against Abstain Broker Non-Votes 17,038,394 9,884,

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 10.1 Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 27, 2024 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR